Navigating the CMS 14-Day Rule in Biomarker TestingVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. David Rimm and Roy Herbst review the problems with the CMS “14-Day Rule” since some of the multigene panel biomarker tests require 21 days or longer to complete.
Dr. Sanjiv Agarwala discusses the pros and cons of using Pembrolizumab over anti-CTLA4 antibody therapy.
Hear Atheer Kaddis describe how the role of the pharmacist is changing in hematology and oncology.Supported through funding from Incyte